Targets › 5-FU
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2028.
Open in Phaseline: the race on 5-FU, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Flucytosine (DB107) Thymidylate synthase inhibitor | 5-FU | Phase 1 | High Grade Glioma | Jan 2028 |
High Grade Glioma (1)
mixed (1)
University of California, San Francisco (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.